UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

~~U.S.~~(Mark ~~SECURITIES AND EXCHANGE COMMISSION~~One)

~~Washington, D.C.~~S ~~20549~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~x QUARTERLY~~For ~~REPORT~~the ~~PURSUANT~~quarter TOended: ~~SECTION~~March 1331, ~~OR 15(d) OF THE~~2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the ~~quarterly~~ transition period ~~ended~~from ~~September~~___________ ~~30,~~to ~~2012~~___________

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 000-52330

AVRA ~~Surgical Robotics~~SURGICAL ROBOTICS, ~~Inc~~INC. (Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)

Delaware		35-2277305
(State or other jurisdiction		(I.R.S. Employer Identification Number)
of incorporation or organization)

c/o Stamell & Schager, LLP, 1 Liberty Plaza, ~~35th~~23rd Floor, New York, NY 10006 (Address of principal executive offices) (212) 566-4047 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (~~Address~~1) has filed all reports required to be filed by Section 13 or 15(d) of ~~principal~~ ~~executive~~the ~~offices~~Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (~~212~~§232.405 of this chapter) ~~566-4047~~ during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes x No o

(Registrant’s telephone number, including area code)

RFG Acquisition II Inc..

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨o Accelerated filer ¨o Non-accelerated filer ¨o Smaller reporting company x. (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ o No x.

~~APPLICABLE~~Indicate ~~ONLY TO~~the ~~ISSUERS~~number ~~INVOLVED~~of INshares ~~BANKRUPTCY~~outstanding ~~PROCEEDINGS~~of ~~DURING~~each of the issuer’s classes of common stock, as of the latest practicable date: 40,422,114 shares of common stock, par value $.0001 per share, outstanding as of May 9, 2013.

THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ¨ No ¨.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 25,329,064 shares of common stock, par value $.0001 per share, outstanding as of November 30 2012.

AVRA SURGICAL ROBOTICS, INC.

- INDEX -

PART I – FINANCIAL INFORMATION:		Page
			Page
Item 1.	Financial Statements:
PART I – FINANCIAL INFORMATION:
	Balance Sheets as of September 30, 2012 (Unaudited) and December 31, 2011	1
Item 1.	Consolidated Financial Statements:
	Statement of Operations (Unaudited) for the Three and Nine Months Ended	2
	Balance Sheets as of March 31, 2013 (Unaudited) and December 31, 2012		1
	September 30, 2012 and 2011, and for the Period from August 29, 2006 (Inception)
	Statements of Operations (Unaudited) for the Three Months Ended March 31, 2013 and 2012, and for the Period from August 29, 2006 (Inception) through March 31, 2013		2
	through September 30, 2012
	Statements of Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2013 and 2012, and for the Period from August 29, 2006 (Inception) through March 31, 2013		3
	Statement of Stockholders’ Equity/(Deficiency) for the Period August 29, 2006	3
	Statement of Stockholders’ Equity/(Deficiency) for the Period August 29, 2006 (Inception) through March 31, 2013 (Unaudited)		4
	(Inception) through September 30, 2012 (Unaudited)
	Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2013 and 2012 and for the Period August 29, 2006 (Inception) through March 31, 2013		5
	Statement of Comprehensive Income (Unaudited) for the Three and Nine Months	4
	Notes to Financial Statements		6
	Ended September 30, 2012 and 2011, and for the Period from
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12
	August 29, 2006 (Inception) through September 30, 2012
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		15
	Statements of Cash Flows (Unaudited) for the Nine Months Ended	5
Item 4.	Controls and Procedures		15
	September 30, 2012 and 2011 and for the Period August 29, 2006 (Inception)
PART II – OTHER INFORMATION:
	through September 30, 2012
Item 1.	Legal Proceedings		17
	Notes to Financial Statements	6
Item 1A.	Risk Factors		17
Item 2.	~~Management’s~~Unregistered ~~Discussion~~Sales ~~and Analysis~~ of ~~Financial~~Equity ~~Condition~~Securities and Use of Proceeds	11	17
	Results of Operations
Item 3.	Defaults Upon Senior Securities		18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Mine Safety Disclosures		18
Item 4.	Controls and Procedures	14
Item 5.	Other Information		18
PART II – OTHER INFORMATION:
Item 6.	Exhibits		18
Item 1.	Legal Proceedings	15
	SIGNATURES		19
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	16
Signatures		18

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

AVRA SURGICAL ROBOTICS, INC. and SUBSIDIARY

AVRA SURGICAL ROBOTICS, INC.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS

	March 31, 2013 Unaudited			December 31, 2012

Assets
Current Assets
Cash	$	540,850		$	406,565
Prepaid expenses		139,116			10,000
VAT refund receivable		97,965			94,551
Total Current Assets		777,931			511,116

Property and Equipment
Machinery and equipment, net of accumulated depreciation of $21,274 and $10,637, respectively		174,974			190,249

Other Assets
Security deposit		10,493			10,493
Patents, net of accumulated amortization of $2,348 and $1,174, respectively		222,234			139,651
Total Other Assets		232,727			150,144

Total Assets	$	1,185,632		$	851,509

Liabilities and Stockholders' Equity/(Deficiency)
Current Liabilities
Accounts payable and accrued expenses	$	2,564,982		$	1,808,049
Loan payable - affiliate		1,632,349		$	1,487,780
Loan payable - stockholder		34,738			34,832
Total Current Liabilities		4,232,069			3,330,661

Total Liabilities		4,232,069			3,330,661

Commitments and Contingencies		-			-

Stockholders' Equity/(Deficiency)
Preferred stock, $.0001 par value; 10,000,000 shares authorized;
none issued and outstanding		-			-
Common stock, $.0001 par value; 100,000,000 shares
authorized; 40,422,114 and 38,479,238 shares, issued and outstanding, respectively		4,042			3,848
Additional paid-in capital		6,784,092			4,873,177
Deficit accumulated during the development stage		(8,899,907	)		(6,730,018	)
Accumulated other comprehensive (loss)		(40,651	)		(48,283	)

Controlling interest		(2,152,424	)		(1,901,276	)

Noncontrolling interests		(894,013	)		(577,876	)

Total Stockholders' Equity/(Deficiency)		(3,046,437	)		(2,479,152	)

Total Liabilities and Stockholders' Equity/(Deficiency)	$	1,185,632		$	851,509

~~(A Development~~See ~~Stage~~Notes ~~Company)~~to Consolidated Financial Statements

CONSOLIDATED BALANCE SHEETS

	September 30, 2012 (Unaudited)			December 31, 2011
Assets
Current Assets
Cash	$	553,910		$	-
Inventory		144,782			-
Prepaid expenses		20,000			-
VAT refund receivable		331,319			-
Total Current Assets		1,050,011			-
Machinery and equipment, Net		82,953			-
Security deposit		11,046			-
Total Assets	$	1,144,010		$	-
Liabilities and Stockholders' Equity/(Deficiency)
Current Liabilities
Accounts payable and accrued expenses	$	134,142		$	-
Due to affiliated company		1,428,756			-
Total Current Liabilities		1,562,898			-
Long Term Liabilities
Loan payable - stockholder		345,810			10,308
Total Long Term Liabilities		345,810			10,308
Total Liabilities		1,908,708			10,308
Commitmenrts and Contingencies		-			-
Stockholders' Equity/(Deficiency)
Preferred stock, $.0001 par value; 10,000,000 shares authorized;
none issued and outstanding		-			-
Common stock, $.0001 par value; 100,000,000 shares
authorized; 25,329,064 and 2,500,000 shares issued and outstanding.respectively		2,533			250
Additional paid-in capital		1,173,400			173,433
Deficit accumulated during the development stage		(1,640,856	)		(183,991	)
Accumulated other comprehensive income		(146	)
Total Stockholders' Deficiency		(465,069	)		(10,308	)
Non-controlling interest		(299,629	)		-
Total Deficiency		(764,698	)		(10,308	)
Total Liabilities and Stockholders' Equity/(Deficiency)	$	1,144,010		$	-

See notes to financial statements.

AVRA SURGICAL ROBOTICS, INC. And SUBSIDIARY

AVRA SURGICAL ROBOTICS, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS
Unaudited

	For the Three Months Ended March 31, 2013			For the Three Months Ended March 31, 2012			For the Period August 29, 2006 (Inception) Through March 31, 2013
Revenues	$	-		$	-		$	-
Expenses:
Research and development		1,428,119			-			4,125,411
General and administrative expenses		1,059,815			13,932			5,652,593
(Loss) before other income/expenses		(2,487,934	)		(13,932	)		(9,778,004	)

Other (income)		-			-			(4,056	)
Interest expense		-			-			16,273
(Loss)before (benefit) from income taxes		(2,487,934	)		(13,932	)		(9,790.221	)
Benefit from income taxes		-			-			-
Net (Loss)	$	(2,487,934	)	$	(13,932	)		(9,790,221	)
Less: Net (loss) attributable to noncontrolling interests		(318,045	)		-			(890,314	)
Net (Loss) Attributable to AVRA Surgical Robotics, Inc.	$	(2,169,889	)	$	(13,932	)	$	(8,899,907	)
Basic and Diluted (Loss) Per Share	$	(0.12	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding		17,483,363			2,500,000

~~(A Development~~See ~~Stage~~Notes ~~Company)~~to Consolidated Financial Statements

CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

	For the Three Months Ended September 30, 2012			For the Three Months Ended September 30, 2011			For the Nine Months Ended September 30, 2012			For the Nine Months Ended September 30, 2011			For the Period August 29, 2006 (Inception) Through September 30, 2012
Revenues	$	-		$	-		$	-		$	-		$	-
Expenses:
Research and development		1,516,050			-			1,516,050			-			1,516,050
General and administrative expenses		224,522			8,226			246,908			23,920			418,682
(Loss) before other income/expenses		(1,740,572	)		(8,226	)		(1,762,958	)		(23,920	)		(1,934,732	)
Other (income)		-			-			-			(4,056	)		(4,056	)
Interest expense		-			496			-			3,229			16,273
(Loss)before (benefit) from income taxes		(1,740,572	)		(8,722	)		(1,762,958	)		(23,093	)		(1,946,949	)
Benefit from income taxes		-			-			-			-			-
Net (Loss)	$	(1,740,572	)	$	(8,722	)	$	(1,762,958	)	$	(23,093	)	$	(1,946,949	)
Less: Net (loss) attributable to non controlling interests		(306,093	)		-			(306,093	)		-			(306,093	)
Net (Loss) Attributable to AVRA Surgical Robotics, Inc.	$	(1,434,479	)	$	(8,722	)	($	1,456,865	)	$	(23,093	)	$	(1,640,856	)
Basic and Diluted (Loss) Per Share	$	(0.08	)	$	(0.00	)	$	(0.19	)	$	(0.01	)
Weighted Average Number of Common Shares Outstanding		18,050,680			2,500,000			7,721,396			2,500,000

See notes to financial statements.

AVRA SURGICAL ROBOTICS,INC. and SUBSIDIARY

AVRA SURGICAL ROBOTICS, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Unaudited

	For the Three Months Ended March 31, 2013			For the Three Months Ended March 31, 2012			For the Period August 29, 2006 (Inception) Through March 31, 2013

Net (loss)	$	(2,487,934	)	$	(13,932	)	$	(9,790,221	)

Foreign currency translation adjustments		9,540			-			(50,814	)

Comprehensive (loss)		(2,478,394	)		(13,932	)		(9,841,035	)

Less: comprehensive (loss) attributable to noncontrolling interests		(316,137	)		-			(900,477	)

Comprehensive (loss) attributable to AVRA Surgical Robotics, Inc.	$	(2,162,257	)	$	(13,932	)		(8,940,558	)

~~(A Development~~See ~~Stage~~Notes ~~Company)~~to Consolidated Financial Statements

Consolidated Statement of Stockholders' Equity/(Deficiency)

For the Period August 29, 2006 (Inception) Through September 30, 2012

	Common Stock						Subscription			Additional			Deficit Accumulated During the Development			Accumulated Other Comprehensive			Noncontrolling			Total Equity/
	Shares			Amount			Receivable			Paid-In Capital			Stage			(Loss)			Interests			(Deficiency)
August 29, 2006 - common stock subscription		2,500,000		$	250		($	250	)	$	-		$	-		$	-		$	-		$	-
August 31, 2006 – contributed capital		-			-			250			29,750			-			-			-			30,000
Net (Loss)		-			-			-			-			(28,511	)		-			-			(28,511	)
Balance at December 31, 2006		2,500,000			250			-			29,750			(28,511	)		-			-			1,489
Net (Loss)		-			-			-			-			(34,932	)		-			-			(34,932	)
Balance at December 31, 2007		2,500,000			250						29,750			(63,443	)		-			-			(33,443	)
Net (Loss)		-			-			-			-			(30,801	)		-			-			(30,801	)
Balance at December 31, 2008		2,500,000			250			-			29,750			(94,244	)		-			-			(64,244	)
Net (Loss)		-			-			-			-			(29,912	)		-			-			(29,912	)
Balance at December 31, 2009		2,500,000			250						29,750			(124,156	)		-			-			(94,156	)
Net (Loss)		-			-			-			-			(30,732	)		-			-			(30,732	)
Balance at December 31, 2010		2,500,000			250			-			29,750			(154,888	)		-			-			(124,888	)
September 16, 2011- Conversion of Loans Payable and Related Accrued Interest to Additional Paid-In Capital		-			-			-			143,683			-			-			-			143,683
September 16, 2011- Sale of Common Stock		2,500,000			250			-			24,750			-			-			-			25,000
September 16, 2011- Purchase of Common Stock		(2,500,000	)		(250	)		-			(24,750	)		-			-			-			(25,000	)
Net (loss)		-			-			-			-			(29,103	)		-			-			(29,103	)
Balance at December 31, 2011		2,500,000			250			-			173,433			(183,991	)		-			-			(10,308	)
July 30,2012- Sale of Common Stock		22,500,000			2,250			-			-			-			-			-			2,250
Sale of Stock in Subsidiary to Related Parties																				6,464			6,464
August 22,2012- Sale of Common Stock		329,064			33			-			999,967			-			-			-			1,000,000
Net (loss)		-			-			-			-			(1,456,865	)		-			(306,093	)		(1,762,958	)
Foreign Currency Translation		-			-			-			-			-			(146	)		-			(146	)
Balance at September 30,2012 (Unaudited)		25,329,064		$	2,533		$	-		$	1,173,400		$	(1,640,856	)	$	(146	)	$	(299,629	)	$	(764,698	)

See notes to financial statements.

AVRA SURGICAL ROBOTICS, ~~INC~~Inc. ~~And SUBSIDIARY~~.

(A Development Stage Company)

CONSOLIDATED ~~STATEMENT~~ STATEMENTS OF ~~COMPREHENSIVE~~STOCKHOLDER’S ~~INCOME~~EQUITY/(DEFICIENCY)

For the Period August 29, 2006 (~~Unaudited~~Inception) Through March 31, 2013

	For the Three Months Ended September 30, 2012			For the Three Months Ended September 30, 2011			For the Nine Months Ended September 30, 2012			For the Nine Months Ended September 30, 2011			For the Period August 29, 2006 (Inception) Through September 30, 2012
	Common Stock						Subscription			Additional Paid-In			Deficit Accumulated During the Development			Accumulated Other Comprehensive			Noncontrolling			Total Equity/
Net (loss)	$	(1,740,572	)	$	(8,722	)	$	(1,762,958	)	$	(23,093	)	$	(1,946,949	)
	Shares			Amount			Receivable			Capital			Stage			(Loss)			Interests			(Deficiency)
Foreign currency translation adjustments		(146	)		-			(146	)		-			(146	)
August 29, 2006 - common stock subscription		2,500,000		$	250		$	(250	)	$	-		$	-		$	-		$	-		$	-
Comprehensive (loss)		(1,740,718	)		(8,722	)		(1,763,104	)		(23,093	)		(1,947,095	)
August 31, 2006 – contributed capital		-			-			250			29,750			-			-			-			30,000
Less: comprehensive loss attributable to noncontrolling interests		306,123			-			306,123			-			306,123
Net (Loss)		-			-			-			-			(28,511	)		-			-			(28,511	)
Comprehensive (loss) attribuatable to AVRA Surgical Robotics, Inc.	$	(1,434,595	)	$	(8,722	)	$	(1,456,981	)	$	(23,093	)	$	(1,640,972	)
Balance at December 31, 2006		2,500,000			250			-			29,750			(28,511	)		-			-			1,489
Net (Loss)		-			-			-			-			(34,932	)		-			-			(34,932	)
Balance at December 31, 2007		2,500,000			250						29,750			(63,443	)		-			-			(33,443	)
Net (Loss)		-			-			-			-			(30,801	)		-			-			(30,801	)
Balance at December 31, 2008		2,500,000			250			-			29,750			(94,244	)		-			-			(64,244	)
Net (Loss)		-			-			-			-			(29,912	)		-			-			(29,912	)
Balance at December 31, 2009		2,500,000			250						29,750			(124,156	)		-			-			(94,156	)
Net (Loss)		-			-			-			-			(30,732	)		-			-			(30,732	)
Balance at December 31, 2010		2,500,000			250			-			29,750			(154,888	)		-			-			(124,888	)
September 16, 2011- Conversion of Loans Payable and Related Accrued Interest to Additional Paid-In Capital		-			-			-			143,683			-			-			-			143,683
September 16, 2011-Sale of Common Stock		2,500,000			250			-			24,750			-			-			-			25,000
September 16, 2011-Purchase of Common Stock		(2,500,000	)		(250	)		-			(24,750	)		-			-			-			(25,000	)
Net (loss)		-			-			-			-			(29,103	)		-			-			(29,103	)
Balance at December 31, 2011		2,500,000			250			-			173,433			(183,991	)		-			-			(10,308	)
Common stock issuance - founders		33,419,254			3,342			-			-			-			-			-			3,342
Sale of stock in subsidiary to related parties		-			-			-			-			-			-			6,464			6,464
Stock based compensation - employees		2,000,000			200						2,999,800												3,000,000
Common stock issuance - cash		559,984			56			-			1,699,944			-			-			-			1,700,000
Net (loss)		-			-			-			-			(6,546,027	)		-			(572,269	)		(7,118,296	)
Foreign Currency Translation		-			-			-			-			-			(48,283	)		(12,071	)		(60,354	)
Balance at December 31,2012		38,479,238			3,848			-			4,873,177			(6,730,018	)		(48,283	)		(577,876	)		(2,479,152	)
Common stock issuance - cash		1,002,376			100			-			1,725,300			-			-			-			1,725,400
Common stock issuance - founders		940,500			94			-			-			-			-			-			94
Stock based compensation		-			-			-			185,615			-			-			-			185,615
Net (loss)		-			-			-			-			(2,169,889	)					(318,045	)		(2,487,934	)
Foreign Currency Translation		-			-			-			-			-			7,632			1,908			9,540
Balance at March 31, 2013		40,422,114		$	4,042					$	6,784,092		$	(8,899,907	)	$	(40,651	)	$	(894,013	)	$	(3,046,437	)

See ~~notes~~ Notes to ~~financial~~Consolidated ~~statements.~~Financial Statements

AVRA SURGICAL ROBOTICS, INC. ~~And~~ ~~SUBSIDIARY~~(A Development Stage Company) CONSOLIDATED STATEMENTS OF CASH FLOWS

(A Development Stage Company)

	For the Three Months Ended March 31, 2013			For the Three Months Ended March 31, 2012			For the Period August 29, 2006 (Inception) Through March 31, 2013
Cash Flows from Operating Activities
Net (loss)	$	(2,487,934	)	$	(13,932	)	$	(9,790,221	)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Stock based compensation expense		185,615			-			3,185,615
Depreciation		10,637			-			21,274
Amortization		1,174			-			2,348
Changes in operating assets and liabilities:
Increase in prepaid expenses		(129,116	)		-			(139,116	)
(Increase) in VAT refund receivable		(3,414	)		-			(97,965	)
Increase (decrease) in accounts payable and accrued expenses		756,933			3,000			2,564,982
Increase in accrued interest payable		-			-			16,273

Net cash (used in) operating activities		(1,666,105	)		(10,932	)		(4,236,810	)

Cash Flows from Investing Activities
Purchase of Machinery and Equipment		4,638			-			(196,248	)
Security deposits		-			-			(10,493	)
Patent costs incurred		(83,757	)		-			(224,582	)
								-
Net cash (used in) investing activities		(79,119	)		-			(431,323	)

Cash Flows from Financing Activities
Professional fees paid by related party on behalf of the company		-			-			7,500
Proceeds from issuance of common stock		1,725,400			-			3,481,586
Proceeds from sale of shares in subsidiary		-			-			6,464
Redemption of common stock		-			-			(25,000	)
Proceeds from affiliate loans		144,569						1,632,349
Proceeds from stockholder loans		-			10,932			156,898

Net cash provided by financing activities		1,869,969			10,932			5,259,797
								-
Effect of exchange rate changes on cash		9,540						(50,814	)

Net increase in cash		134,285			-			540,850

Cash at beginning of period		406,565			-			-

Cash at end of period	$	540,850		$	-		$	540,850

Supplemental Disclosures of Cash Flow Information
Cash paid for:
Interest	$	-		$	-		$	-
Income taxes	$	-		$	-		$	-

Non-cash Financing Activities:
Conversion of loan payable - stockholder to common stock	$	94		$	-		$	2,250
Conversion of loans payable - stockholders and related accrued interest to additional paid-in capital		-			-			136,183
Conversion of loans payable - related party to additional paid-in capital		-			-			7,500

	$	94		$	-		$	145,933

~~CONSOLIDATED STATEMENTS~~See OFNotes ~~CASH~~to ~~FLOWS~~Consolidated Financial Statements

(Unaudited)

	For the Nine Months Ended September 30, 2012			For the Nine Months Ended September 30, 2011			For the Period August 29, 2006 (Inception) Through September 30, 2012
Cash Flows from Operating Activities
Net (loss)	$	(1,762,958	)	$	(23,093	)	$	(1,946,949	)
Adjustments to reconcile net (loss) to net cash used in operating activities:
Increase in prepaid expenses		(20,000	)		-			(20,000	)
(Increase) in inventory		(144,782	)		-			(144,782	)
(Increase) in security deposit		(11,046	)		-			(11,046	)
(Increase) in VAT refund receivable		(331,319	)		-			(331,319	)
Increase in accounts payable and accrued expenses		134,142			4,038			134,142
Increase in accrued interest		-			3,229			-
Net cash (used in) operating activites		(2,135,963	)		(15,826	)		(2,319,954	)
Cash Flows from Investing Activities
Purchase of Machinery and Equipment		(82,953	)		-			(82,953	)
Net cash (used in) investing activites		(82,953	)					(82,953	)
Cash Flows from Financing Activities
Professional fees paid by related party on behalf of the company		-			7,500			-
Loans from affiliated company		1,428,756			-			1,428,756
Proceeds from issuance of common stock		1,002,250			25,000			1,175,933
Proceeds from sale of shares in subsidiary		6,464			-			6,464
Redemption of common stock		-			(25,000	)		-
Proceeds from stockholder loans		335,502			8,400			345,810
Net cash provided by financing activities		2,772,972			15,900			2,956,963
Effect of exchange rate changes on cash		(146	)		-			(146	)
Net increase in cash		553,910			74			553,910
Cash at beginning of period		-			66			-
Cash at end of period	$	553,910		$	140		$	553,910
Supplemental Disclosures of Cash Flow Information
Cash paid for:
Interest	$	-		$	3,229		$	16,273
Income Taxes	$	-		$	-		$	-
Non-cash Financing Activities:
Conversion of loans payable - stockholders and related accrued interest to additional paid-in capital	$	-		$	136,183		$	136,183
Conversion of loans payable - related party to additional paid-in capital		-			7,500			7,500

See notes to financial statements.

AVRA SURGICAL ROBOTICS, INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

~~September 30~~March 31, ~~2012~~2013

NOTE 1 - ORGANIZATION AND BUSINESS: AVRA Surgical Robotics, Inc. ("AVRA Robotics" or the "Company"), including its 80% owned subsidiary MIS-Robotics GmbH (“MIS”), is a Development Stage Company. The Company's former Chief Executive Officer ("CEO") and former Chief Scientist and Technical Officer ("CSTO") own the remaining 20% of MIS equally. As of March 31, 2013, the Company has not generated any revenues from the development of its products and is therefore still considered to be a development stage company as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915 “Development Stage Entities”. The Company is devoting substantially all of its present efforts to design and manufacture commercially viable surgical robotic systems. All losses accumulated since incorporation on August 29, 2006 have been considered as part of the Company's development stage activities.

AVRA Surgical Robotics, Inc. ("AVRA Robotics" or the "Company"), including its 80% owned subsidiary MIS-Robotics GmbH, company (“MIS”), is a Development Stage Company. As of September 30, 2012, the Company has not generated any revenues from the development of its products and is therefore still considered to be a development stage company as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915 “Development Stage Entities”. The Company is devoting substantially all of its present efforts to design and manufacture commercially viable surgical robotic systems. All losses accumulated since incorporation on August 29, 2006 have been considered as part of the Company's development stage activities.

NOTE 2 - BASIS FOR PRESENTATION FOR INTERIM FINANCIAL STATEMENT:

The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted for interim financial statement presentation and in accordance with the instructions to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statement presentation. In the opinion of management, all adjustments for a fair statement of the results of operations and financial position for the interim period presented have been included. All such adjustments are of normal recurring nature. This financial information should be read in conjunction with the Financial Statements and notes thereon included in the Company’s form 10-K for the fiscal year ended December 31, ~~2011~~2012.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation: The consolidated financial statements include the accounts of AVRA Surgical Robotics, Inc. and its 80% owned subsidiary MIS. All intercompany transactions and accounts have been eliminated in consolidation. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~(a)~~Loss ~~Principles~~per ofCommon ~~Consolidation~~Share:

~~The~~Basic ~~consolidated~~loss ~~financial statements~~per ~~include~~share is calculated using the ~~accounts~~weighted-average number of ~~AVRA~~common ~~Surgical~~shares ~~Robotics,~~outstanding ~~Inc~~during each reporting period. ~~and~~Diluted ~~its~~loss ~~80%~~per ~~owned~~share ~~subsidiary~~includes ~~MIS-Robotics~~potentially ~~GmbH.~~dilutive ~~All~~securities ~~intercompany transactions~~such as outstanding options and ~~accounts~~warrants, ~~have~~using ~~been~~various ~~eliminated~~methods such as the treasury stock or modified treasury stock method in ~~consolidation~~the determination of dilutive shares outstanding during each reporting period. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive. As of March 31, 2013, common stock equivalents consisted of warrants convertible into 950,000 shares of common stock.

(b) Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~AVRA~~NOTE ~~SURGICAL ROBOTICS~~3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED): Patents: Patents are stated at cost and depreciated on a straight line basis over the estimated lives of the respective assets. The useful lives for patents are estimated to be twenty years from the filing date. Research and Development Costs: Costs related to research,~~INC~~ design and development of products are charged to research and development expense as incurred. The costs include direct salary costs for research and development personnel, costs for materials used in research and development activities and costs for outside services. Software Development Costs: Software development costs are included in research and development and are expensed as incurred. After technological feasibility is established, material software development costs are capitalized. The capitalized costs are then amortized on a straight-line basis over the estimated product life, or on the ratio of current revenue to total projected product revenue, whichever is greater. To date, the period between achieving technological feasibility, which the Company has defined as the establishment of a working model, which typically occurs when the verification and validation testing is complete, and the general availability of such software has been short and software development costs qualifying for capitalization have been insignificant. Accordingly, the Company has not capitalized any software development costs to date. Stock Compensation Expense: The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification ("ASC") Topic 505, “ Equity ”. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505. See Note 8 Concentration of Credit Risk: Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash is held in demand accounts at large financial institutions (of which $140,624 was held in a German bank). On occasion, deposits are in excess of insured limits. The Company has not experienced any historical losses on its deposits of cash and cash equivalents.

(A Development Stage Company)

Notes to Consolidated Financial Statements

September 30, 2012

NOTE 3- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED):

The Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. There are no cash equivalents at the balance sheet dates.

(d) Income Taxes:

The Company utilizes the liability method of accounting for income taxes. Under the liability method deferred tax assets and liabilities are determined based on the differences between financial reporting basis and the tax basis of the assets and liabilities and are measured using enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized.

The Company recognizes the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount recognized in the financial statements is the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. As of September 30, 2012, the Company is unaware of any uncertain tax positions.

(e) Loss per Common Share:

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

(f) Research and Development Costs:

Costs related to research, design and development of products are charged to research and development expense as incurred. The costs include direct salary costs for research and development personnel, costs for materials used in research and development activities and costs for outside services.

(g) Foreign Currency Translation

The Company accounts for foreign currency translation pursuant to Accounting Standards Codification ("ASC") Topic 830 “Foreign Currency Matters”. The functional currency of the Company’s subsidiary, MIS, is the Euro. Under ASC Topic 830, all assets and liabilities are translated into United States dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. Translation adjustments are included in other comprehensive income (loss) for the period.

~~AVRA~~Recent ~~SURGICAL ROBOTICS,INC.~~Accounting Pronouncements:

In February 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-02, Comprehensive Income (ATopic ~~Development Stage~~220)—Reporting ~~Company~~of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02), to improve the reporting of reclassifications out of accumulated other comprehensive income. ASU 2013-02 requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety from accumulated other comprehensive income to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. ASU 2013-02 is effective for the Company in its first quarter of fiscal 2014 with earlier adoption permitted, which should be applied prospectively. The Company does not expect that adoption of this guidance during fiscal 2014 will have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

~~Notes~~Management ~~to Consolidated~~does ~~Financial~~not ~~Statements~~believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

~~September 30,~~NOTE ~~2012~~4 - GOING CONCERN:

~~NOTE~~The 4accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a development stage entity and has incurred a cumulative net loss from inception of $9,790,221 and has a stockholders’ deficiency of $3,046,437 which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management’s plan to raise additional capital from the sale of stock, receive additional loans from its affiliate, and ultimately, income from operations. The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying ~~RECENT~~amounts ~~ACCOUNTING~~or ~~PRONOUNCEMENTS:~~the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

~~Management does~~NOTE ~~not~~5 - COMMON ~~believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.~~STOCK:

In 2012 we adopted the provisions of Accounting Standards Update (ASU) 2011−05, “Presentation of Comprehensive Income” (ASU 2011−05) that requires presentation of all non−owner changes in equity in one continuous statement of comprehensive income or in two separate but consecutive statements. We elected to provide a separate statement of comprehensive income for all periods presented. The amendments in this update do not change the items that must be reported in other comprehensive income (OCI) or when an OCI item must be reclassified to net income. The adoption of ASU 2011−05 did not affect our consolidated statements of financial position, results of operations and cash flows.

ASU 2011−05 was modified in December 2011 by the issuance of ASU 2011−12, “Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011−05.” This update indefinitely defers certain provisions of ASU 2011−05 that require the disclosure of the amount of reclassifications of items from OCI to net income by component of net income and by component of OCI.

NOTE 5 - GOING CONCERN:

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a development stage entity and has incurred a cumulative net loss from inception of approximately $1,640,856 and has a deficit of $764,698, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management’s plan to raise additional capital from the sale of stock, receive additional loans from its majority stockholder, and ultimately, income from operations. The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

AVRA SURGICAL ROBOTICS,INC.

(A Development Stage Company)

Notes to Consolidated Financial Statements

September 30, 2012

NOTE 6 - COMMON STOCK:

The Company is authorized to issue one hundred million (100,000,000) shares of common stock. On August 29, 2006 the Company sold two million five hundred thousand (2,500,000) shares of common stock to two investors for $250, which was paid on August 31, 2006.

On ~~July~~ 30January 31, ~~2012~~2013, the Company ~~issued~~sold 22to three investors,~~500~~ including the Company’s then President, 350,000 shares of common stock at par and issued warrants for 100,000 shares of common stock with an exercise price of $5.00 per share and expiring on December 31, 2016 to ~~its~~two ~~then~~of ~~sole~~the ~~shareholder~~investors atand ~~par~~a ~~value~~warrant to purchase 400,000 shares of common stock with an exercise price of $5.00 per share and expiring on December 31, 2015 to the Company’s then President.

On ~~August~~ 22February 12, ~~2012~~2013, the Company ~~sold~~filed ~~329~~a Registration Statement with the SEC providing for the registration of up to $17,~~064~~000,000 ~~shares~~(net of $15,150,000 after expenses) of common stock to ~~one~~be ~~investor~~offered to public stockholders. The filing can be referenced at www.sec.gov. The number of shares to be issued is at present undetermined. The proceeds from the offering are expected to be used for ~~$1,000,000~~research and development of the Company’s surgical robotic system as well as general and administrative expenses.

~~NOTE~~On 7February -20, ~~PREFERRED~~2013, ~~STOCK:~~the Company sold 633,597 shares of common stock to eleven investors for $950,400.

~~The Company~~On March is12, ~~authorized~~2013, tothe ~~issue~~Company ~~ten~~sold ~~million (10~~117,~~000,000)~~371 shares of ~~$.0001~~common ~~par value preferred~~ stock ~~with designations, voting and other rights and preferences as may be determined from time~~ to ~~time~~an byinvestor ~~the~~for ~~Board of Directors of the Company~~$250,000.

~~NOTE~~ 8 ~~- RELATED PARTY TRANSACTIONS:~~

~~The Company~~NOTE ~~utilizes~~5 – COMMON STOCK (CONTINUED): On March 25, 2013, the ~~office~~Company ~~space~~sold (i) 234,742 shares of common stock to an investor for $500,000; (ii) 16,666 shares to an investor for $25,000; and ~~equipment~~(iii) 590,500 shares of ~~its~~common ~~management~~stock to three investors at nopar ~~cost~~and a warrant to purchase 400,000 shares of common stock, exercisable at an exercise price of $5.00 per share expiring on December 31, 2015 to one of the investors.

NOTE 6 - PREFERRED STOCK: The Company’s ~~subsidiary,~~is ~~MIS,~~authorized ~~leases~~to ~~office~~issue ~~space~~ten inmillion ~~Seefeld~~(10,000,000) ~~Germany~~shares ~~from~~of a$.0001 ~~shareholder~~par ~~under~~value apreferred ~~three-year~~stock ~~lease~~with ~~commencing August 1~~designations, ~~2012. The~~voting ~~monthly~~and ~~rent~~other rights and ~~utilities~~preferences ~~total~~as ~~€2,363.46~~may ~~plus~~be ~~19%~~determined ~~Value~~from ~~Added~~time ~~Tax~~to ~~("VAT"). The lease~~time ~~may~~by bethe ~~extended~~Board ~~for~~of ~~one~~Directors ~~year~~of the Company. NOTE 7 - WARRANTS: Warrant activity is as follows:

On May 16, 2011, the Company entered into an agreement with Granite Investor Group, Inc. (“Granite”), that provided Granite, or an affiliate of Granite, with an option to purchase such number of common shares of the Company as shall be required to obtain control of the Company for an aggregate purchase price of $25,000, which would be used by the Company to repurchase the shares of common stock currently issued and outstanding. In accordance with the agreement, Granite agreed to reimburse the Company for expenses incurred after May 16, 2011, the date of the agreement, that relate to complying with reporting obligations pursuant to the Securities Exchange Act of 1934.

	Warrants outstanding		Weighted average exercise price		Weighted average remaining life

Balance, January 1, 2013		50,000	$	5.00		3.75
Granted		900,000	$	5.00		2.83
Exercised		-		-		-
Cancelled		-		-		-
Balance, March 31, 2013 (fully vested)		950,000	$	5.00		2.88

~~Prior to~~On January 31, 2013, the Company issued warrants for 100,000 shares of common stock with an exercise price of ~~the~~$5.00 ~~option,~~per ~~Granite~~share ~~reimbursed~~and ~~the~~expiring ~~company~~on December 31, 2016 and a ~~total~~warrant for 400,000 shares of common stock with an exercise price of $45.00 per share,~~056~~ ~~which~~expiring ison ~~reported~~December as31, ~~other~~2015. ~~income~~The ~~during~~warrants were outstanding at March 31, 2013. On March 25, 2013, the ~~year ended~~Company issued a warrant for 400,000 shares of common stock with an exercise price of $5.00 per share and expiring on December 19, 2015. The warrant was outstanding at March 31, ~~2011~~2013. NOTE 8 - STOCK BASED COMPENSATION:

~~In connection~~The ~~with~~Company ~~the~~uses ~~exercise of~~ the ~~option,~~Black-Scholes onpricing ~~September~~model ~~16,~~to ~~2011,~~determine the ~~Company~~fair ~~issued~~value ~~and~~of ~~sold~~stock anoptions. ~~aggregate~~The determination of ~~2,500,000~~the ~~shares~~ fair value of ~~Common~~stock-based ~~Stock~~payment toawards ~~Granite~~on ~~for~~the andate ~~aggregate~~of ~~purchase~~grant ~~price~~is ~~equal~~affected toby ~~$25,000,~~our ~~which~~stock ~~amount~~price ~~was~~as ~~used~~well toas ~~repurchase~~assumptions ~~2,500,000~~regarding ~~shares of~~a ~~Common~~number ~~Stock~~of ~~held~~complex byand ~~Richard~~subjective Fvariables. ~~Beston,~~These variables include the Company'’s ~~President~~expected ~~and~~stock aprice ~~director~~volatility ~~immediately~~over ~~prior to~~ the ~~transaction~~term ~~and John W.~~of ~~Branch~~the awards, ~~the~~actual ~~Company's~~and ~~Secretary~~projected ~~immediately~~employee ~~prior~~stock tooption ~~the~~exercise ~~transaction~~behaviors, ~~for~~risk-free aninterest ~~aggregate~~rates ~~purchase~~and ~~price~~expected ~~equal to $25,000~~dividends. The ~~repurchased~~ ~~shares~~estimated ~~were~~grant ~~then~~date ~~cancelled.~~fair Avalues ~~change~~ of ~~control of~~ the ~~Company~~employee ~~resulted~~stock ~~upon~~options ~~the~~for ~~closing of~~ the ~~transaction.~~periods ~~New~~presented ~~officers~~ were ~~appointed~~calculated tousing ~~serve~~the asBlack-Scholes ~~President,~~valuation ~~Treasurer~~model, ~~and~~based ~~Secretary,~~on ~~effective~~the ~~upon~~following ~~resignation of Mr. Beston and Mr. Branch.~~assumptions:

	Three months ended March 31,
	2013
Expected volatility		56%
Risk-free interest rate		0.4%-0.6%
Expected term (in years)		3 - 4
Expected dividend rate		0%

During the three months ended March 31, 2013 and 2012, stock-based compensation expense, reported as General and Administrative Expense, was $185,615 and $0 respectively.

NOTE 9 - RELATED PARTY TRANSACTIONS:

Agreement with Affiliated Company:

On October 22, 2012, MIS entered into a joint development and manufacturing agreement (the "Agreement") with RG Mechatronics GmbH (“RGM”) whereby RGM will provide to MIS all engineering services necessary to develop and manufacture robotic components and systems for medical applications, (collectively, the "Products"). The Company's former (as of March 1, 2013) CSTO is an officer and employee of RGM. The Agreement further provides that MIS will own all rights to intellectual property arising from RGM's performance under the Agreement, subject to RGM's nonexclusive, nontransferable, right in any area other than for medical purposes to exploit the intellectual property.

The term of the Agreement is the longer of (i) two years from October 22, 2012 or (ii) for each Product development which commences within two years from October 22, 2012, upon completion of the Product.

As part of the Agreement, MIS and RGM established a joint development committee ("JDC") with a representative from each party. On October 23, 2012, the JDC met and agreed to (i) performance and design specifications of the Products, (ii) the budget for development of the Products, and (iii) the timeline for developing the Products.

~~AVRA~~NOTE ~~SURGICAL ROBOTICS,INC.~~9 - RELATED PARTY TRANSACTIONS (CONTINUED):

(AAccounts ~~Development Stage~~payable includes $1,260,790 due to RGM under the Agreement. These amounts together with prior payments are disputed. For the three months ended March 31, 2013, the Company) incurred $1,428,119 of research and development expenses with RGM, all of which has been charged to operations.

~~Notes~~On April 8, 2013, the Company, through MIS, notified RGM of its intention to ~~Consolidated~~ ~~Financial~~terminate ~~Statements~~the Agreement, subject to certain legal formalities. On the same date, RGM provided the Company, through MIS, a notice of immediate termination of the Agreement for cause.

~~September 30,~~Loans ~~2012~~Due to Affiliated Entities:

~~NOTE~~Loan 8payable -to ~~RELATED~~affiliate ~~PARTY~~($1,632,349) ~~TRANSACTIONS~~and loan payable to stockholder (~~CONTINUED~~$34,738): represent amounts due to AVRA Surgical, Inc., and Granite Investor Group, Inc. respectively, each company majority owned by two of the Company’s officers and directors. The amounts represent advances to the Company to fund initial research and development expenses incurred under the Agreement between MIS and RGM. These amounts are unsecured, non-interest bearing and have no stipulated repayment terms.

~~Professional fees~~One inof the ~~amount~~Company’s ofdirectors ~~$7,500~~is ~~were~~also ~~paid~~a onpartner ~~behalf~~ of the ~~Company~~legal byfirm ~~Ten~~used Xfor ~~Holdings,~~much ~~LLC~~of ~~(“Ten~~the ~~X”),~~Company’s anlegal ~~affiliate~~services. For of the ~~Company.~~three ~~The~~months ~~amount~~ended ~~was~~March ~~unsecured~~31, ~~non-interest~~2013, ~~bearing~~legal ~~and~~fees ~~had~~incurred ~~no stipulated repayment terms. In accordance~~ with the ~~agreement entered~~firm ~~into~~totaled ~~with Granite~~$331,805. As ~~a non-refundable deposit~~ of $5March 31,~~000,~~ ~~paid by Granite~~2013, ~~was~~such ~~received~~fees byhave ~~Ten~~not Xbeen paid and ~~applied~~are toreflected ~~the~~on ~~outstanding loan balance. As of September 16, 2011,~~ the ~~outstanding~~consolidated balance ofsheet ~~$2,500~~as ~~was~~accounts ~~converted to paid-in capital~~payable.

~~As of~~ Employment ~~September 16, 2011, the liability to Granite for the non-refundable deposit of $5,000, paid by Granite, was converted to additional paid-in capital.~~Agreements:

~~During the~~The ~~nine~~Company ~~months~~entered ~~ended~~into ~~September~~separate ~~30,~~individual ~~2012,~~employment ~~fees~~agreements inwith the ~~amount~~CEO ofand ~~$337~~CSTO,~~752~~ ~~were~~each ~~paid~~with ona ~~behalf~~term of ~~the~~five ~~Company~~(5) byyears ~~Granite.~~ending ~~The~~on ~~outstanding balance~~August ~~of $345~~1,~~810~~ is2017 ~~reported~~and asan ~~loan~~annual ~~payable~~base –salary ~~stockholder~~of atapproximately ~~September 30~~$390, ~~2012~~000. ~~The~~In ~~amount~~addition, isthe ~~unsecured,~~Company ~~non-interest bearing~~will pay pension and ~~has~~other nobenefits ~~stipulated~~as ~~repayment~~well ~~terms~~as reimbursement of business expenses.

~~During~~ Effective February 8, 2013 the ~~nine~~CEO ~~months~~resigned ~~ended~~from ~~September~~his ~~30,~~position ~~2012,~~and RGwas ~~Mechatronics~~appointed ~~GmbH~~Senior ~~(“RGM”),~~Vice aPresident ~~company~~for ~~owned~~Marketing bywith his employment agreement remaining otherwise in full force and effect and a ~~stockholder~~new ~~provided $2~~CEO was appointed. On March 1,~~075~~ 2013,~~104~~ ofthe ~~research~~CSTO ~~and~~terminated ~~development~~his employment agreement with the Company and ~~other~~resigned ~~services~~as toan ~~MIS~~officer. ~~The~~On ~~balance~~March at29, ~~September 30~~2013, ~~2012~~the CEO was $1appointed President of the Company in addition to his CEO role. On April 19,~~428~~ 2013,~~756~~ ~~See~~the ~~Note~~Company ~~9 (Subsequent~~served ~~Events).~~a complaint in a case filed in New York State court against its former CSTO. The complaint alleges that the former CSTO breached his duty of loyalty to the Company's ~~Chief~~by ~~Executive~~attempting ~~Officer~~to ~~("CEO"),~~misappropriate ~~Stephan~~its ~~Sagolla,~~business and ~~Chief~~business ~~Scientific~~opportunities and ~~Technical Officer~~seeks ~~("CSTO"),~~monetary ~~Bernd Gombert~~damages, ~~each~~interest ~~individually~~and ~~own~~costs ~~10%~~from ~~of MIS~~him.

~~The~~NOTE ~~Company~~10 ~~employs~~- ~~the~~LEASE ~~CEO~~COMMITMENT: ~~and~~MIS ~~CSTO~~leases ~~under~~its ~~separate~~office ~~individual agreements~~premises in Seefeld, ~~each~~Germany ~~with~~from a ~~term~~company ofowned ~~five~~by ~~(5)~~the ~~years~~former ~~ending~~CSTO onunder a three-year agreement commencing August 1, ~~2017~~2012 ~~and~~at ana ~~annual~~monthly ~~base~~rate ~~salary~~ of ~~€300~~approximately $3,000, plus 19% V.A.T. InThe ~~addition~~Company is liable for maintenance, insurance and taxes. The lease may be extended for one year. Rent expense for the three months ended March 31, 2013 was approximately $9,400. The Company ~~will~~occupies ~~pay~~its ~~pension~~New ~~and~~York ~~other~~Offices, ~~benefits~~without ascost, ~~well~~from asthe ~~reimbursement~~law firm of ~~business~~which ~~expenses~~the Secretary and Treasurer is a partner. The Company estimates the value to be immaterial.

NOTE 9 11 - INCOME ~~SUBSEQUENT EVENTS~~TAXES:

~~On October~~At 22March 31, ~~2012~~2013, the Company’s ~~80%~~had ~~owned~~available ~~subsidiary~~approximately $5,340,000 ~~MIS~~of ~~entered~~net ~~into~~operating aloss ~~joint~~carry-forwards ~~development~~for ~~and~~U.S. ~~manufacturing~~income ~~agreement~~tax ~~(the "Agreement")~~purposes ~~with~~which ~~RGM~~expire tothrough ~~provide~~2032. toIn addition, MIS ~~all~~has ~~engineering~~German ~~services~~net ~~necessary~~operating toloss ~~design~~carry ~~and~~forwards ~~manufacture~~of ~~surgical~~approximately ~~robotic components and systems (collectively~~$4,452,000, ~~the~~with ~~"Products").~~no ~~The~~expiration ~~Company's CSTO is an officer and employee of RGM~~date.

The ~~Agreement~~ ~~further~~Company’s ~~provides~~deferred ~~that~~tax ~~MIS~~assets ~~will~~at ~~own~~March ~~all rights to intellectual property arising from RGM's work~~31, ~~subject~~2013 toand ~~RGM's nonexclusive~~2012, ~~nontransferable~~ ~~right~~based inon ~~any~~net ~~area~~operating ~~other~~loss ~~than~~carry ~~for~~forwards, ~~medical~~are ~~purposes~~approximately ~~to exploit the intellectual property. The term of the Agreement is the longer of two years from October 22~~$3,330,000 ~~2012~~and ~~or for each Product development which commences within two years from October 22~~$55,000, ~~2012~~respectively, ~~upon~~with ~~completion~~a ofvaluation allowance in the ~~Product~~same amount.

As part of the Agreement, MIS and RGM established a joint development committee ("JDC") with a representative from each party. On October 23, 2012, the JDC met and agreed to performance and design specifications of the Products, the budget for development of the Products, and the timeline for developing the Products.

NOTE 11 - INCOME TAXES (CONTINUED):

Actual income tax/(benefit) differs from the expected tax /(benefit) computed by applying the U.S federal corporate rate of 34% to income/(loss) before income taxes as follows:

	For the quarters ended
	March 31,
	2013			2012

Computed expected tax benefit	$	(846,000	)	$	(5,000	)
Change in valuation allowance		846,000			5,000

	$	-0-		$	-0-

Due to the uncertainty of their realization, no income tax benefit has been recorded by the Company for these net operating loss carry forwards as valuation allowances have been established for any such benefits. The increase in the valuation allowance was the result of increases in the net operating losses discussed above. Therefore, the Company’s provision for income taxes is $0 for the quarters ended March 31, 2013 and 2012.

At March 31, 2013 and 2012, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. At March 31, 2013 and 2012, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company currently has no federal or state tax examinations in progress nor has it had any federal or state examinations since its inception. The 2009 through 2012 tax years generally remain subject to examination by federal and state tax authorities.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statement Notice

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) in regard to the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of AVRA Surgical Robotics, Inc. (“we”, “us”, “our” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company's plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

~~Description of Business~~ Overview

~~The Company~~We ~~was~~are ~~incorporated~~a indevelopment ~~the~~stage ~~State~~company ofand ~~Delaware~~have onnot ~~August~~earned ~~29,~~any ~~2006~~revenues ~~(Inception)~~from ~~under~~operations ~~the~~to ~~name~~date. ~~"RFG~~It ~~Acquisition~~is IIunlikely ~~Inc." and~~that ~~maintains~~we ~~its~~will ~~principal~~have ~~executive~~any ~~office~~revenues atunless ~~c/o~~and ~~Stamell~~until &our ~~Schager,~~products ~~LLP,~~are 1ready ~~Liberty~~for ~~Plaza~~commercial ~~35th~~manufacturing ~~Floor,~~and ~~New~~have ~~York,~~received NYregulatory ~~10006. Since~~approval ~~inception,~~in the ~~Company~~markets ~~has~~where ~~been~~they ~~engaged~~will inbe ~~organizational~~sold. ~~efforts~~Since ~~and~~inception, ~~obtaining~~the ~~initial financing. The~~ Company ~~was~~has ~~formed as~~relied aprimarily ~~vehicle~~on tosales ~~pursue a business combination through the acquisition~~ of, orour ~~merger~~securities ~~with,~~to anfund ~~operating~~our ~~business~~operations. The Company ~~filed a~~has ~~Registration~~never ~~Statement~~been onprofitable ~~Form 10-SB with the U.S. Securities~~ and ~~Exchange~~cannot ~~Commission~~be ~~(the~~assured ~~“SEC”)~~that onwe ~~November~~will ~~22, 2006,~~be ~~and~~profitable ~~since~~in ~~its effectiveness,~~ the ~~Company~~future. ~~has~~From ~~focused~~inception ~~its~~through ~~efforts~~March ~~to identify a possible business combination. Effective August 3~~31, ~~2012~~2013, ~~we changed~~ our ~~business~~loss ~~purpose and focus~~ from ~~pursuing~~operations atotaled ~~business combination to designing~~$9,790,221 ~~developing~~ and ~~manufacturing surgical~~our ~~robotic~~net ~~systems~~loss ~~(the~~for ~~"Change of Business"). In connection with~~ the ~~Change~~three ofmonths ~~Business,~~ended onMarch ~~August 3~~31, ~~2012,~~2013 ~~our board~~totaled ~~of directors appointed new management~~$2, ~~including Stephan Sagolla~~487, ~~as the Chief Executive Officer of the Company and Bernd Gombert as the Company's Chief Scientist and Technical Officer~~934.

~~In addition~~Our toprincipal business objective for the ~~changes~~next to12 ~~our~~months ~~management,~~and inbeyond ~~order~~such time will be to ~~better~~achieve ~~reflect~~long-term ~~the~~growth ~~Company's~~potential ~~Change~~by ofdevoting ~~Business,~~our onefforts ~~August~~to 3designing, ~~2012,~~developing ~~the Company~~and ~~also~~manufacturing ~~changed~~surgical ~~its~~robotic ~~name~~systems. In order to ~~"AVRA~~attain ~~Surgical~~this ~~Robotics~~goal, ~~Inc."~~we, ~~For~~through ~~the~~our ~~purpose~~80% ofowned ~~effecting~~subsidiary, MIS, entered into the ~~name~~Development ~~change~~Agreement with RGM, onan ~~July 11~~engineering company. On April 8, ~~2012~~2013, the Company, ~~incorporated~~through aMIS, ~~wholly-owned~~notified ~~subsidiary~~RGM ~~("Merger~~of ~~Sub")~~its ~~under~~intention ~~the~~to ~~laws~~terminate of the ~~State~~Development ofAgreement ~~Delaware, in~~with ~~the~~immediate ~~name~~effect, ~~"AVRA~~subject ~~Surgical~~to ~~Robotics,~~certain ~~Inc~~legal formalities.". On ~~August~~the 3same date, ~~2012~~RGM provided the Company, ~~Merger~~through ~~Sub~~MIS, ~~was~~a ~~merged~~notice ~~with~~of ~~and~~immediate ~~into~~termination of the ~~Company,~~Development ~~with the~~Agreement for cause. The Company ~~continuing~~intends asto continue the ~~surviving~~product ~~corporation~~development ~~and~~using ~~adopting~~another ~~the~~engineering ~~name~~company ofunless ~~Merger~~the ~~Sub~~dispute is resolved.

~~On July~~The ~~17,~~Company ~~2012,~~expects ~~the~~to ~~Company~~continue ~~formed~~to arequire ~~German~~substantial ~~limited~~funds ~~liability~~for ~~company~~research ~~named~~and ~~MIS-Robotics~~development, ~~GMbH~~to (“continue to develop our MIS”) ~~under~~system. ~~the~~The ~~laws of~~Company ~~Germany,~~plans ~~which~~to ismeet ~~80%~~our ~~owned~~operating cash flow requirements by raising additional funds from the ~~Company~~sale of our securities and, ~~10%~~whenever ~~owned~~possible, by ~~Stephan~~entering ~~Sagolla~~into ~~and~~development ~~10%~~partnerships ~~owned~~to byassist ~~Bernd~~us ~~Gombert~~with our technology development activities. We may also consider selling certain assets or entering into a transaction such as a merger with a business complimentary to ours.

~~We are~~During the three months ended March 31, 2013, the Company has raised an aggregate of $1,725,400 in connection with the ~~development~~closing ~~stage~~of private placement offerings of the Company’s common stock and warrants. While we have ~~not~~been ~~earned~~successful ~~any~~in ~~revenues~~raising ~~from~~funds to fund our operations tosince ~~date.~~inception ~~These conditions~~and ~~raise~~we ~~substantial~~believe ~~doubt~~that ~~about~~we ~~our~~will ~~ability~~be successful in obtaining the necessary financing to ~~continue~~fund asour aoperations going ~~concern. The~~forward, ~~Company’s~~we ~~principal business~~do ~~objective~~not ~~for~~have ~~the~~any ~~next~~committed 12sources ~~months~~of funding and ~~beyond~~there are no assurances that we will be able to ~~achieve~~secure ~~long-term~~additional ~~growth~~funding. ~~potential~~The byaccompanying ~~devoting~~financial ~~our~~statements ~~efforts~~have ~~to designing~~been ~~and~~prepared ~~manufacturing~~assuming ~~surgical~~that ~~robotic~~the ~~systems~~Company ~~with~~will ~~our~~continue ~~own~~as ~~resources~~a orgoing byconcern; ~~entering~~however, ~~into~~if athe ~~joint~~efforts ~~development~~noted ~~plan~~above ~~or agreement~~are ~~with~~not ~~another~~successful, ~~entity.~~it ~~Our~~would raise substantial doubt about the Company’s ability to continue as a going concern. isIf ~~dependent~~we ~~upon~~cannot ~~our~~obtain ~~ability~~financing, then we may be forced to ~~generate~~further ~~profits~~curtail ~~from~~ our operations ~~and/~~or toconsider ~~obtain~~other ~~the~~strategic ~~necessary~~alternatives. ~~financing~~Even toif ~~meet~~we ~~our~~are ~~obligations~~successful ~~and~~in ~~repay~~raising ~~our~~the ~~liabilities~~additional ~~when~~financing, ~~they~~there ~~come~~is ~~due.~~no Inassurance ~~addition, our~~regarding ~~ability~~the toterms ~~continue~~of asany aadditional ~~going~~investment ~~concern~~and isany ~~also~~such ~~dependent~~investment ~~upon~~or ~~our~~other ~~ability~~strategic toalternative ~~develop~~would ~~additional~~likely ~~sources~~substantially ofdilute ~~capital~~our current stockholders.

As of the date of the period covered by this report, the Company had $553,910 in cash. There are no assurances that the Company will be able to secure any additional funding as needed. Management’s plan includes obtaining additional funds by equity financing and/or related party advances, however there is no assurance of additional funding being available.

Liquidity and Capital Resources

As of September 30, 2012, the Company had a deficit of $764,698. The Company can provide no assurance that it can continue to satisfy its cash requirements for at least the next twelve months.

We will continue to require substantial funds to advance the development of robotic products. We intend to meet our operating cash flow requirements by raising additional funds from the sale of equity or issuance of debt and pursuing strategic partnerships to advance our product development. While we believe that we will be successful in obtaining the necessary financing to fund our operations going forward, we do not have any committed sources of funding and there are no assurances that we will be able to secure additional funding.

Operating Activities

Net cash used in operating activities for the nine month period ended September 30, 2012 increased $2,120,137 from $15,826 for the nine month period ended September 30, 2011 to $2,135,963. Net cash used in operating activities during the nine month period ended September 30, 2012 was primarily the result of a net loss of $1,762,958.

Investing Activities

Net cash used in investing activities during the nine month period ended September 30, 2012 was $82,953, which was primarily used for machinery and equipment purchases. We expect to continue to purchase property and equipment in the normal course of our business. The amount and timing of these purchases and the related cash outflows in future periods is difficult to predict and is dependent on a number of factors, including, but not limited to, any increase in the number of our employees and changes related to our product development programs. Net cash used in investing activities during the nine month period ended September 20, 2011 was $0.

Financing Activities

Net cash provided by financing activities during the nine month period ended September 30, 2012 was $2,772,972 which was the result of proceeds of $1,002,250 from the sale of the Company's common stock, $1,428,756 of loans from an affiliated company, proceeds of $6,464 from the sale of shares in the Company's subsidiary and proceeds of $335,502 from stockholder loans.

Emerging Growth Company

We are an “emerging growth company” under the federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the “Securities Act”) for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards.

Liquidity and Capital Resources

As of March 31, 2013, the Company had $540,850 in cash and a stockholders’ deficiency of $3,046,437. This compares with $0 cash and a stockholders’ deficiency of $24,240 as of March 31, 2012. The Company had liabilities that totaled $4,232,069 as of March 31, 2013, comprised of $2,564,982 in accounts payable and accrued expenses and $1,667,087 in a loan payable to affiliates and stockholders. This compares to the Company’s total liabilities of $24,240 as of March 31, 2012, comprised of accounts payable and accrued expenses and a loan payable to a stockholder. The Company can provide no assurance that it can continue to satisfy its cash requirements for at least the next twelve months.

The Company raised $1,725,400 in equity capital during the three months ended March 31, 2013 through a series of private placements. The Company is dependent on its ability to continue to raise equity capital. On February 12, 2013, the Company filed a Registration Statement on Form S-1 (the “Registration Statement”) with the SEC to register shares in order to raise up to $17,000,000 (net of $15,150,000 after expenses). There is no guarantee that the proposed sale of shares under the Registration Statement will be successful and if not successful, the Company will need to seek other avenues for the necessary capital to continue its development program.

The following is a summary of the Company’s cash flows provided by (used in) operating, investing, and financing activities for the three months ended March 31, 2013 and 2012 and for the period from August 29, 2006 (Inception) through March 31, 2013:

	Three Months Ended March 31, 2013			Three Months Ended March 31, 2012			For the Cumulative Period from August 29, 2006 (Inception) to March 31, 2013

Net Cash (Used in) Operating Activities	$	(1,666,105	)	$	(10,932	)	$	(4,236,810	)
Net Cash (Used in) Investing Activities	$	(79,119	)		-		$	(431,323	)
Net Cash Provided by Financing Activities	$	1869,969		$	10,932		$	5,259,797
Effect of Exchange Rate Changes on Cash	$	(9,540	)		-		$	(50,814	)
Net Increase (Decrease) in Cash	$	134,285			-		$	540,850

The increase since the three months ended March 31, 2012 in cash available is a result of an increase in sales of the Company’s securities in order to fund the Company’s operations. The increase in accounts payable and accrued expenses in the three months ended March 31, 2013 is a result of the Company changing its business purpose and beginning operations.

The Company has nominal assets and has generated no revenues since inception. The Company is also dependent upon the receipt of capital investment or other financing to fund its ongoing operations. In addition, the Company is dependent upon obtaining additional funding and capital resources through equity financings and from certain related parties. If continued funding and capital resources are unavailable at reasonable terms, the Company may not be able to implement its plan of operations.

Results of Operations

~~No revenue~~Three ~~has~~months ~~been~~ended ~~generated~~March ~~by the Company from August 29~~31, ~~2006~~2013 ~~(inception)~~as ~~through~~compared September 30, 2012. It is unlikely the Company will have any revenues unless and until its products are ready for manufacturing and have received regulatory approval in the markets where they will be sold. The Company expects to ~~begin sales within~~ the ~~next~~three ~~twelve~~ months, ~~but~~ended ~~there~~March is31, no assurance that the Company will succeed in generating revenues or when revenues will begin to be generated. The Company’s plan of operation for the next twelve months is to continue its efforts to raise additional capital and pursue strategic partnerships to advance its product development. 2012

~~For~~We ~~the~~have ~~three~~not ~~and~~conducted ~~nine month~~any ~~periods~~active ~~ended~~operations ~~September~~since 30inception except hiring our initial employees, ~~2012~~entering into the Development Agreement and ~~2011,~~commencing ~~research~~its implementation through our 80% owned subsidiary MIS including building prototypes and ~~development~~manufacturing ~~expense~~key ~~totaled~~components. $1We have generated no revenue since inception on August 29,~~516,050~~ 2006. It is unlikely we will generate any revenue until our products are developed and ~~$0,~~have ~~respectively~~been approved for sale. ~~This represents~~The toCompany’s plan of operation for the ~~purchase~~next oftwelve ~~in-process~~months ~~research~~shall be to continue its efforts to design, develop and ~~development~~manufacture surgical robotic systems.

For the three ~~month periods~~months ended ~~September~~March 3031, ~~2012 and 2011~~2013, ~~general~~we ~~and~~had ~~administrative~~a ~~expenses~~net ~~totaled~~loss ~~$224,522~~of ~~and~~ $82,~~226~~487,934 ~~respectively.~~consisting ~~This represents~~of anresearch ~~increase~~and development expenses of $~~216~~1,~~296~~428,119, ~~from~~incurred ~~the~~primarily ~~prior~~through ~~period. For~~ the ~~nine~~Development ~~month~~Agreement ~~periods ended September 30, 2012~~ and ~~2011,~~ general and administrative expenses ~~totaled~~consisting ~~$246~~of compensation,~~908~~ ~~and~~of which $23185,~~920~~615 is stock based, ~~respectively.~~legal ~~This~~expenses ~~represents~~for anthe ~~increase~~formation of ~~$222,988,~~the ~~which~~Company isand for the ~~result~~ ofwork ~~our~~on ~~change~~the inRegistration ~~business~~Statement, toalong ~~focus~~with onvarious ~~the~~other ~~development~~travel ofand ~~surgical~~occupancy ~~robotic systems~~items.

For the three ~~month~~months ~~periods~~ ended ~~September~~March 3031, 2012 ~~and 2011~~, ~~the~~we ~~Company~~ had a net loss of $113,~~740~~932,~~572~~ ~~and~~consisting $8of legal,~~722~~ accounting, ~~respectively. For~~audit, ~~the~~and ~~nine~~other ~~month~~professional ~~periods~~service ~~ended~~fees ~~September~~incurred ~~30,~~in ~~2012~~relation ~~and~~to ~~2011,~~ the ~~Company~~preparation ~~had~~and afiling ~~net~~of ~~loss~~our ofperiodic ~~$1,762,958~~reports and ~~$23~~general,~~093~~ administrative, ~~respectively~~and interest expenses.

For the cumulative period from August 29, 2006 (~~inception~~Inception) ~~through~~to ~~September~~March 3031, ~~2012~~2013, ~~the~~we ~~Company~~ had a net loss of $19,~~946~~790,~~949~~221 ~~consisting of (i) $1,516,050 of research and development, (ii) $418,682 of general and administrative expenses~~ comprised of legal, accounting, audit, and other professional service fees incurred in relation to the formation of the Company, the filing of ~~the~~our ~~Company’s~~ Registration Statement on Form 10-SB in November of 2006, and the ~~filing~~Registration ofStatement, the ~~Company’s~~preparation ~~Quarterly Reports on Form 10-QSB~~ and ~~Form~~ ~~10-Q and the~~ filing of ~~the~~our ~~Company’s~~periodic ~~Annual Reports on Form 10-KSB~~reports, and ~~Form~~general, ~~10-K; (iii) $16~~administrative,~~273~~ ofand interest ~~expense; and (iv) $4,056 of other income~~expenses.

Critical Accounting Policies

For a summary of our critical accounting policies, please see Note 3 to our financial statements, which are included in this report.

Recently Issued Accounting Pronouncements

For a discussion of recently issued accounting pronouncements, please see Note 3 to our financial statements, which are included in this report.

Off-Balance Sheet Arrangements

~~The Company~~As ~~does~~of May 15, 2013, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Trends, Events and Uncertainties

The following trends, events and uncertainties may have a material impact on our potential sales, revenue and income from operations:

	1)	completion of our surgical robotic products ready for manufacturing;
	2)	regulatory approval of our products in the markets where we desire to sell them;
	3)	market acceptance of our products by surgeons and patients in the markets where we desire to sell them;
	4)	our ability to efficiently manufacture, market and distribute our products;
	5)	our ability to sell our products at competitive prices which are profitable;
	6)	the willingness of surgeons to learn to use our products; and
	7)	the willingness of insurers and national health plans to reimburse patients for robotic surgeries at prices which are profitable.

To the extent we are unable to succeed in accomplishing (1) through (7), our sales could be lower than expected and our ability to generate income from operations impaired.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations is based on the consolidated financial statements of the Company, which have been prepared in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

Research and Development Costs

Recently Issued Accounting Pronouncements

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

~~We maintain~~The Company’s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that ~~are~~is designed to ensure that information required to be disclosed by the Company in ~~our~~the reports ~~filed~~ ~~pursuant~~that tothe Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the ~~SEC~~Commission’s rules, ~~regulations~~and forms. Disclosure controls and ~~related~~procedures ~~forms~~include, without limitation, controls and ~~that~~procedures ~~such~~designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to ~~our~~the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

~~As of~~In ~~September~~accordance ~~30,~~with ~~2012,~~Exchange weAct ~~carried~~Rules ~~out~~13a-15 and 15d-15, an evaluation, was completed under the supervision and with the participation of ~~our~~the ~~principal~~Company’s ~~executive officer~~management, ~~and~~including ~~our~~the ~~principal~~Company’s ~~financial~~Chief ~~officer~~Executive Officer, Principal Financial Officer and Secretary, of the effectiveness of the design and operation of ~~our~~the Company’s disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on ~~this~~that evaluation, ~~our~~the ~~principal~~Company’s ~~executive~~management ~~officer~~including ~~and~~the ~~our~~Chief ~~principal~~Executive ~~financial~~Officer, ~~officer~~Principal Financial Officer and Secretary, concluded that ~~our~~the Company’s disclosure controls and procedures were effective asin ofproviding reasonable assurance that information required to be disclosed in the ~~end~~Company’s ofreports filed or submitted under the ~~period~~Exchange ~~covered~~Act bywas ~~this~~recorded, ~~report~~processed, summarized, and reported within the time periods specified in the Commission’s rules and forms.

~~Changes in~~Evaluation of Internal Controls and Procedures

~~There have~~Our ~~been~~management nois ~~changes~~also inresponsible ~~our~~for establishing and maintaining adequate internal ~~controls~~control over financial reporting. The ~~during~~Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the ~~quarter~~reliability ~~ended~~of ~~September~~financial ~~30,~~reporting ~~2012~~and ~~that~~the ~~have~~preparation ~~materially affected~~of orfinancial ~~are~~statements ~~reasonably~~for ~~likely~~external topurposes ~~materially~~in ~~affect~~accordance ~~our~~with ~~internal~~generally ~~controls~~accepted accounting principles.

1415

Our internal control over financial reporting includes those policies and procedures that:

●	Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
●	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of the Company’s management and sole director; and

●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2013. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control over Financial Reporting – Guidance for Smaller Public Companies. Based on our assessment of those criteria, management believes that the Company maintained effective internal control over financial reporting as of March 31, 2013.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permits us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

There have been no significant changes to the Company’s internal controls over financial reporting that occurred during our last fiscal quarter of the year ended March 31, 2013, that materially affected, or were reasonably likely to materially affect, our internal controls over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

~~There are~~On ~~presently~~April no19, ~~material~~2013, ~~pending legal proceedings to which~~ the Company, ~~any~~served ofa ~~its~~complaint ~~subsidiaries,~~in ~~any~~a ~~executive~~case ~~officer,~~filed ~~any owner~~in ofNew ~~record~~York orstate ~~beneficially~~court ofagainst ~~more~~Mr. ~~than~~Bernd ~~five~~Gombert, ~~percent~~its offormer ~~any~~CSTO ~~class~~and ofExecutive ~~voting~~Vice ~~securities~~President. The iscomplaint aalleges ~~party~~that orMr. asGombert tobreached ~~which~~his ~~any~~duty of ~~its property~~loyalty isto ~~subject,~~the ~~and~~Company noby ~~such~~attempting ~~proceedings~~to ~~are~~misappropriate ~~known~~its tobusiness ~~the~~and ~~Registrant~~business toopportunities beand ~~threatened~~seeks ormonetary ~~contemplated~~damages, ~~against~~interest itand costs.

Item 1A. Risk Factors.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On ~~July~~ 30January 31, ~~2012~~2013, the Company issued and sold an aggregate of 22350,~~500,~~000 shares of common stock toand ~~Granite~~issued ~~Investor~~(1) ~~Group~~warrants for 100,000 ~~Inc~~shares of common stock with an exercise price of $5.00 per share and expiring on December 31, 2016 (~~"Granite"~~the “2016 Warrant”) ~~for~~ anand ~~aggregate~~(2) warrants to purchase 400,000 shares of common stock with an exercise price of $5.00 per share and expiring on December 31, 2015 (the “2015 Warrants”) to three accredited investors, including Dr. Sudhir Srivastava, our former President, at a per share price equal to $~~2,250~~0.0001 for aggregate gross proceeds of $35.00 pursuant to the terms and conditions of athose certain securities purchase ~~agreement~~agreements, dated January 31, 2013 (the “~~Granite~~ January Purchase ~~Agreement~~Agreements”).

On ~~August~~ 21February 20, ~~2012~~2013, the Company issued and sold an aggregate of ~~329~~633,~~064~~597 shares of common stock to ~~HeartWare,~~eleven ~~Inc.,~~accredited ainvestors ~~Delaware~~at ~~corporation ("HeartWare")~~a ~~for~~price anper ~~aggregate~~share ~~purchase price~~ equal to $1.50 for aggregate gross proceeds of $950,~~000,000~~400 pursuant to the terms and conditions of athose ~~common~~certain ~~stock purchase~~Securities ~~agreement~~Purchase Agreements, dated February 20, 2013 (the ~~"HeartWare~~“February Purchase ~~Agreement"~~Agreements”).

~~The shares~~On ofMarch ~~common~~12, ~~stock~~2013, ~~sold pursuant to~~ the ~~Granite~~Company ~~Purchase~~issued ~~Agreement~~ and ~~HeartWare~~sold ~~Purchase~~an ~~Agreement~~aggregate ~~were issued in connection with the exemption from registration provided by Section 4(2) under the Securities Act~~ of ~~1933~~117,371 asshares ~~amended~~of ~~(the~~common ~~“Securities Act”)~~stock asto ~~a transaction by~~ an ~~issuer~~accredited ~~not~~investor ~~involving~~at a ~~public~~price ~~offering,~~per inshare ~~which~~equal ~~the~~to ~~investor~~$2.13 ~~is accredited and has acquired the securities~~ for ~~investment~~aggregate ~~purposes~~gross ~~only~~proceeds ~~and~~of ~~not~~$250,000 ~~with~~pursuant ~~a view~~ to orthe ~~for~~terms ~~sale~~and inconditions ~~connection~~of ~~with~~that ~~any~~certain ~~distribution~~Securities ~~thereof.~~Purchase ~~The Company~~Agreement, ~~did~~dated ~~not~~March ~~pay~~12, ~~any~~2013 ~~commissions~~(the in“March ~~connection~~Purchase ~~with either sale of the shares~~Agreement”).

~~The terms~~On ofMarch ~~the~~25, ~~Granite~~2013, ~~Purchase~~the ~~Agreement~~Company issued and ~~HeartWare~~sold ~~Purchase~~(i) ~~Agreement~~an ~~described~~additional ~~herein~~590,500 isshares ~~intended~~of common stock to bethree accredited investors at a ~~summary~~price ~~only~~per share equal to $0.0001 and is ~~qualified~~a warrant to purchase 400,000 shares of common stock, exercisable at an exercise price of $5.00 per share and expiring on December 31, 2015, substantially in ~~its~~the ~~entirety~~form byof the ~~terms~~2015 ~~and~~Warrants, ~~conditions~~to one of the ~~Granite~~investors ~~Purchase~~pursuant ~~Agreement~~to ~~and~~certain ~~HeartWare~~Securities Purchase ~~Agreement~~Agreements ~~filed~~ dated as ~~Exhibits~~of 10March 25, 2013 (the “Subsequent Initial Offering Purchase Agreements”) for aggregate gross proceeds of approximately $59.105; ~~and~~(ii) 10an additional 16,666 to an accredited investor at a price per share equal to $1.250 pursuant to a certain Securities Purchase Agreement substantially in the form of the February Purchase Agreement for aggregate gross proceeds of approximately $25,000; ~~respectively~~and (iii) an additional 234,742 shares of common stock to ~~this~~an ~~quarterly~~accredited ~~report~~investor onat ~~Form~~a ~~10-Q~~price per share equal $2.13 pursuant to a certain Securities Purchase Agreement substantially in the form of the March Purchase Agreement for aggregate gross proceeds of approximately $500,000.

No brokers or finders were used and no commissions or other fees have been paid by the Company in connection with the sale of securities described above. The sales of the securities identified above were made pursuant to privately negotiated transactions that did not involve a public offering of securities and, accordingly, were exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof and the rules promulgated thereunder. Each of the above-referenced investors represented to us, as applicable, in connection with their investment that they were “accredited investors” (as defined by Rule 501 under the Securities Act) and were acquiring the shares for investment and not for distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The investors received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. The sales of the foregoing securities were made without any form of general solicitation or advertising and all of the foregoing securities are deemed restricted securities for purposes of the Securities Act.

The terms of the 2016 Warrant, the 2015 Warrant, the January Purchase Agreement, the February Purchase Agreement, the March Purchase Agreement and the Subsequent Initial Offering Purchase Agreement described herein are intended to be a summary only and are qualified in their entirety by the terms and conditions of the 2016 Warrant, the 2015 Warrant, the January Purchase Agreement, the February Purchase Agreement, the March Purchase Agreement and the Subsequent Initial Offering Purchase Agreement filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, to this quarterly report on Form 10-Q.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~The information~~On ~~set~~March ~~forth~~1, in2013, ~~Item~~the 2CSTO isterminated ~~incorporated~~his ~~herein~~employment byagreement ~~this~~with ~~reference~~the Company and resigned as an officer.

On ~~October~~ ~~22,~~March ~~2012~~12, ~~MIS-Robotics GmbH~~2013, ~~a German limited liability company ("MIS") and 80% owned subsidiary of AVRA Surgical Robotics, Inc~~Dr. ~~(the~~Sudhir ~~"Company"),~~Srivastava ~~entered~~resigned ~~into~~from ~~a joint development and manufacturing agreement (~~the ~~"Agreement") with~~office RGof ~~Mechatronics~~President ~~GmbH,~~of ~~a German corporation ("RGM") for RGM to provide to MIS all engineering services to develop and manufacture robotic components and systems for medical applications (~~the ~~"Purpose"), including the infrastructure to manufacture such products (collectively, the "Products"). Bernd Gombert, the~~ Company~~'s Chief Scientist and Technical Officer as of August 3, 2012, is an officer and employee of RGM~~.

The term of the Agreement is the longer of (i) two years from October 22, 2012 or (ii) upon the fulfillment of the Purpose for each Product the development of which commences within two years from October 22, 2012 unless earlier terminated pursuant to the terms therein. The Purpose for each Product will be deemed complete upon RGM's delivery and MIS's acceptance of the null series of the Product ready for manufacturing. Pursuant to the terms and conditions of the Agreement, MIS and RGM have agreed to establish a joint development committee ("JDC") consisting of at least one representative from each party to specify (i) the performance and design specifications of the Products, (ii) the budget for development of the Products, including RGM's remuneration for engineering services rendered, and (iii) the timeline for developing the Products. In addition, MIS has agreed to pay RGM for its work, labor and services on a time and material basis in accordance with the development budget established by the JDC, which may be adjusted from time-to-time for significant increases or decreases in the costs incurred by RGM.

The Agreement further provides that MIS will own all rights to any intellectual property arising from RGM's performance under the Agreement (the "Intellectual Property") and, to the extent that such rights cannot be transferred, RGM will grant MIS an indefinite, exclusive, sub-licenseable, transferrable, unlimited worldwide right to use and exploit such Intellectual Property, subject to RGM's nonexclusive, nontransferable, sub-licenseable right in any area other than for medical purposes to use and exploit the Intellectual Property.

The Agreement may be terminated by either party (i) with one month notice if they fail to agree on any issue presented to them by the JDC after one month and (ii) without notice if the other party commits a material breach of the Agreement and fails to cure within one month after the non-breaching party provides written notice of such breach.

The terms of the Agreement described herein is intended to be a summary only and is qualified in its entirety by the terms and conditions of the Agreement attached to this quarterly report on Form 10-Q as Exhibit 10.3.

On October 5, 2012, the Company entered into an employment agreement with Bernd Gombert (the "Employment Agreement"). Pursuant to the terms and conditions of the Employment Agreement, the Company agrees to employ Mr. Gombert as the Chief Scientist and Technical Officer of the Company, for a term of five (5) years, commencing on or about August 2, 2012 unless earlier terminated pursuant to the terms therein. Mr. Gombert will receive an annual base salary of €300,000, subject to annual review and increases by the Company's board of directors, as it deems appropriate. His base salary will be paid monthly on the last day of each month. In addition to his base salary, the Company has agreed to pay the following expenses: (i) €15,000, paid monthly at the end of each month, in full compensation for any Social Security assessments, health insurance and any analogous charges assessed based on income; (ii) €48,000, paid at the end of each calendar year, into a private pension fund for Mr. Gombert's benefit; (iii) all leasing and operating costs arising from Mr. Gombert's use of the Company's car; (iv) four weeks of paid vacation time per year; (v) continued base salary for up to twelve months of disability; (vi) severance pay for six months at the base salary rate, plus accrued benefits, including all vested stock options in the event that he is terminated by the Company during the first two years of his employment; (vii) executive compensation in the form of options or shares, or both, under any long-term equity compensation plan that may be adopted by the Company; and (viii) other business expenses reasonably incurred for promoting the Company's business. Upon any termination, Mr. Gombert will be entitled to unpaid accrued salary and benefits as of the termination date. If Mr. Gombert chooses to resign and, thus, terminate his employment with the Company, he will not own, manage or control any business that directly competes with the Company, its subsidiaries or affiliates for the two-year period thereafter; however, if the Company terminates his employment, the non-compete period will be co-extensive with the number of months for which Mr. Gombert would be entitled to severance pay.

The foregoing description of the terms and conditions of the Employment Agreement is intended to be a summary only and is qualified in its entirety by the terms and conditions of the form of the Employment Agreement attached hereto as Exhibit 10.4 and incorporated herein by this reference.

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation S-K.

	Exhibit	Description
Exhibit No.		Description	Incorporation by Reference
	*3.1	Certificate of Incorporation, as filed with the Delaware Secretary of State on August 29, 2006.
			Form	Exhibit	Filing Date
	*3.2	By-Laws.
3.1		Certificate of Ownership and Merger filed with the Office of Secretary of State of Delaware on August 3, 2012	8-K	3.1	08/07/2011
*	*3.3	Certificate of Ownership and Merger, as filed with the Delaware Secretary of State on August 3, 2012.
3.2		Certificate of Incorporation	10-SB		11/22/2006
	10.1	Securities Purchase Agreement with Granite Investor Group, Inc., dated July 30, 2012.
3.3		Bylaws	10-SB		11/22/2006
	10.2	Common Stock Purchase Purchase Agreement with HeartWare, Inc., dated August 21, 2012.
10.1		Form of 2016 Warrant, dated January 31, 2013*
	10.3	Joint Development and Manufacturing Agreement, dated October 22, 2012.
10.2		Form of 2015 Warrant, dated January 31, 2013	8-K	10.2	01/07/2013
	10.4	Form of Employment Agreement with Bernd Gombert, dated October 5, 2012
10.3		Form of January Purchase Agreement, dated January 31, 2013	8-K	10.1	01/07/2013
10.4		Form of February Purchase Agreement, dated February 20, 2013	10-K	10.10	04/01/2013
10.5		Form of March Purchase Agreement, dated March 12, 2013*
10.6		Form of Subsequent Initial Purchase Agreement, dated March 25, 2013	8-K	10.3	01/07/2013
31.1		Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012
31.2		Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012
32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
32.1		Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101.INS		XBRL INSTANCE DOCUMENT
101.SCH		XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
101.CAL		XBRL TAXONOMY CALCULATION LINKBASE DOCUMENT
101.DEF		XBRL TAXONOMY DEFINITION LINKBASE DOCUMENT
101.LAB		XBRL TAXONOMY LABEL LINKBASE DOCUMENT
101.PRE		XBRL TAXONOMY PRESENTATION LINKBASE DOCUMENT

16* Filed herewith.

31.1 Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.18

31.2 Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

32.1 Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* Filed as an exhibit to the Company’s Registration Statement on Form 10-SB, as filed with the SEC on November 22, 2006 and incorporated herein by this reference.

** Filed as an exhibit to the Company's Current Report on Form 8-K, as filed with the SEC on August 7, 2012 and incorporated herein by this reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AVRA SURGICAL ROBOTICS, INC.
Dated: November 30 2012	By: /s/ Barry F. Cohen
Dated: May 15, 2013	By:	/s/ Barry F. Cohen
	~~Barry F. Cohen~~	Barry F. Cohen
	President and Director
		Chief Executive Officer, President and Director Principal Executive Officer
	Principal Executive Officer
Dated: May 15, 2013	By:	/s/ A. Christian Schauer
Dated: November 30 2012	By: /s/ Jared B. Stamell
		A. Christian Schauer Chief Financial Officer Principal Financial Officer
	Jared B. Stamell
	Secretary, Treasurer and Director
	Chief Financial Officer
	Principal Financial Officer

18 19

Filing Compare · AVRA Surgical Robotics, Inc.